Sigyn Therapeutics, Inc. (SIGY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

-150K 0 150K 300K 450K Q3 '14: 13.5K Q4 '14: 973 Q1 '15: 10.8K Q2 '15: 18.4K Q3 '15: 0 Q4 '15: 0 Q1 '17: 268.9K Q2 '17: 432.5K Q3 '17: 256K Q1 '18: 23.1K Q2 '18: 5.8K Q3 '18: 90.5K Q4 '18: -1 Q1 '19: 41.6K Q2 '19: 64.3K Q3 '19: 32.1K Q4 '19: 5.3K Q1 '20: 756 Q2 '20: 0 Q3 '20: 3.8K Q4 '14 Q3 '15 Q2 '17 Q2 '18 Q1 '19 Q4 '19 Q3 '20

Gross Profit Quarterly

-90K 0 90K 180K 270K Q3 '14: 8.8K Q1 '15: 7.8K Q2 '15: 11.5K Q3 '15: 0 Q4 '15: 0 Q1 '17: 192.9K Q2 '17: 247.3K Q3 '17: 157.5K Q1 '18: 13.5K Q2 '18: 5.8K Q3 '18: 77.8K Q4 '18: -1 Q1 '19: 32.3K Q2 '19: 47.5K Q3 '19: 24.1K Q4 '19: 3.8K Q1 '20: 493 Q2 '20: 0 Q3 '20: 2K Q3 '14 Q3 '15 Q2 '17 Q2 '18 Q1 '19 Q4 '19 Q3 '20

Operating Income Quarterly

-900K -600K -300K 0 300K 600K 900K Q4 '20: -344.6K Q1 '21: -402.1K Q2 '21: -441.8K Q3 '21: -573.4K Q4 '21: -590.9K Q1 '22: -609.2K Q2 '22: -532.8K Q3 '22: -533.6K Q4 '22: -471.6K Q1 '23: -521.3K Q2 '23: -574K Q3 '23: -642.8K Q4 '23: -717.2K Q1 '24: -630K Q2 '24: -602.8K Q3 '24: -808.5K Q4 '24: -478K Q1 '25: -546.1K Q2 '25: -469.5K Q3 '25: -386.5K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Net Income Quarterly

-1.5M -1M -500K 0 500K 1M 1.5M Q4 '20: -452K Q1 '21: -461.7K Q2 '21: -649.9K Q3 '21: -665.9K Q4 '21: -1.2M Q1 '22: -678K Q2 '22: -666.3K Q3 '22: -726.5K Q4 '22: -858.9K Q1 '23: -1.3M Q2 '23: -723.1K Q3 '23: -905.7K Q4 '23: -1.2M Q1 '24: -758.1K Q2 '24: -862.4K Q3 '24: -1.2M Q4 '24: -522.8K Q1 '25: -668.6K Q2 '25: -1.5M Q3 '25: -578.5K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Cost of Revenue Quarterly

0 70K 140K 210K Q1 '17: 76K Q2 '17: 185.3K Q3 '17: 98.5K Q1 '18: 9.7K Q2 '18: 71K Q3 '18: 12.7K Q4 '18: 0 Q1 '19: 9.2K Q2 '19: 16.8K Q3 '19: 8K Q4 '19: 1.6K Q1 '20: 263 Q2 '20: 0 Q3 '20: 1.8K Q2 '17 Q1 '18 Q3 '18 Q1 '19 Q3 '19 Q1 '20 Q3 '20

Operating Cash Flow Quarterly

-600K -400K -200K 0 200K 400K 600K Q4 '20: -280.8K Q1 '21: -274.4K Q2 '21: -407.1K Q3 '21: -539.7K Q4 '21: -553K Q1 '22: -459.6K Q2 '22: -394.7K Q3 '22: -524.2K Q4 '22: -451.8K Q1 '23: -562.6K Q2 '23: -328.7K Q3 '23: -364K Q4 '23: -127.9K Q1 '24: -235.6K Q2 '24: -182.8K Q3 '24: -163.8K Q4 '24: -290.2K Q1 '25: -294.4K Q2 '25: -152.4K Q3 '25: -199.3K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Free Cash Flow Quarterly

-600K -400K -200K 0 200K 400K 600K Q1 '16: -320.9K Q2 '16: -165.6K Q3 '16: -106.4K Q1 '17: -108.4K Q2 '17: -75.6K Q3 '17: 2.1K Q4 '17: -219K Q4 '18: 10.2K Q1 '21: -277.3K Q2 '21: -407.1K Q3 '21: -557K Q4 '21: -562K Q3 '22: -524.2K Q4 '22: -451.8K Q2 '16 Q1 '17 Q3 '17 Q4 '18 Q2 '21 Q4 '21 Q4 '22

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '19: 81.3M Q3 '19: 541.8K Q1 '20: 500K Q2 '20: 500K Q3 '20: 500K Q1 '21: 35.3M Q2 '21: 36.4M Q3 '21: 36.7M Q1 '22: 37.3M Q2 '22: 37.3M Q3 '22: 37.3M Q1 '23: 961.6K Q2 '23: 1.1M Q3 '23: 1.1M Q1 '24: 1.2M Q2 '24: 1.2M Q3 '24: 1.3M Q1 '25: 1.6M Q2 '25: 1.6M Q3 '25: 1.6M Q3 '19 Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '20: -0.17 Q1 '21: 0.32 Q2 '21: 0.82 Q3 '21: 1.39 Q4 '21: -0.08 Q1 '22: -0.09 Q2 '22: -0.09 Q3 '22: -0.09 Q4 '22: -3.13 Q1 '23: -4.50 Q2 '23: -5.15 Q3 '23: -5.95 Q4 '23: -3.82 Q1 '24: -3.05 Q2 '24: -3.08 Q3 '24: -3.20 Q4 '24: -2.51 Q1 '25: -2.31 Q2 '25: -2.51 Q3 '25: -1.93 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.